Patents Assigned to FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
  • Publication number: 20190054191
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 150 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Application
    Filed: December 1, 2016
    Publication date: February 21, 2019
    Applicant: Friedrich Miescher Institute for Biomedical Research
    Inventors: Dominik HARTL, Josephine JUETTNER, Arnaud KREBS, Botond ROSKA, Dirk SCHUEBELER
  • Patent number: 10179917
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in Muller cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: January 15, 2019
    Assignee: FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Botond Roska, Josephine Juettner
  • Publication number: 20180355377
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Application
    Filed: December 1, 2016
    Publication date: December 13, 2018
    Applicant: Friedrich Miescher Institute for Biomedical Research
    Inventors: Dominik HARTL, Josephine JUETTNER, Arnaud KREBS, Botond ROSKA, Dirk SCHUEBELER
  • Publication number: 20180353617
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 300 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Application
    Filed: December 1, 2016
    Publication date: December 13, 2018
    Applicant: Friedrich Miescher Institute for Biomedical Research
    Inventors: Dominik HARTL, Josephine JUETTNER, Arnaud KREBS, Botond ROSKA, Dirk SCHUEBELER
  • Publication number: 20180346529
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 300 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Application
    Filed: December 1, 2016
    Publication date: December 6, 2018
    Applicant: Friedrich Miescher Institute for Biomedical Research
    Inventors: Dominik HARTL, Josephine JUETTNER, Arnaud KREBS, Botond ROSKA, Dirk SCHUEBELER
  • Publication number: 20180298378
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 600 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal endothelial cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Application
    Filed: October 13, 2016
    Publication date: October 18, 2018
    Applicant: Friedrich Miescher Institute for Biomedical Research
    Inventors: Josephine JUETTNER, Botond ROSKA
  • Publication number: 20180256753
    Abstract: The present invention relates to an isolated nucleic acid molecule comprising a nucleotide sequence coding for a depolarizing light-gated ion channel functionally linked to a promoter leading to the specific expression of said depolarizing light-gated ion channel in a retinal photoreceptor, or the nucleotide sequence complementary to said nucleotide sequence, for use in treating or ameliorating blindness. The present invention also relates to methods of using such nucleic acid molecules in the treatment of blindness.
    Type: Application
    Filed: September 13, 2016
    Publication date: September 13, 2018
    Applicant: Friedrich Miescher Institute for Biomedical Research
    Inventors: Josephine JUETTNER, Dasha NELIDOVA, Botond ROSKA
  • Publication number: 20180208928
    Abstract: The present inventions relates to isolated nucleic acid molecules comprising a nucleotide sequence coding for miRNA-182 (uuuggcaaugguagaacucacacu or ugguucuagacuugccaacua), miRNA-96 (uuuggcacuagcacauuuuugcu or aaucaugugcagugccaauaug) and/or miRNA-183 (uauggcacugguagaauucacu or gugaauuaccgaagggccauaa) for use in treating or ameliorating a ciliopathy and/or a photoreceptor dysfunction.
    Type: Application
    Filed: December 6, 2017
    Publication date: July 26, 2018
    Applicant: FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Volker Busskamp, Witold Filipowicz, Jacek Krol, Botond Roska
  • Patent number: 9999685
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO: 1 or a nucleic acid sequence of at least 200 bp having at least 70% identity to the sequence of SEQ ID NO: 1, wherein the isolated nucleic acid molecule specifically leads to the expression in retinal amacrine bipolar cells of a gene when operatively linked to a nucleic acid sequence coding for the gene.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: June 19, 2018
    Assignee: FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Botond Roska, Josephine Juettner
  • Publication number: 20180125925
    Abstract: The present invention relates to the use of an isolated nucleic acid molecule comprising a nucleotide sequence coding for a hyperpolarizing light-gated ion channel or pump gene from an archeon or for a light-active fragment of said gene, or the nucleotide sequence complementary to said nucleotide sequence, for treating or ameliorating blindness. The light-gated ion channel or pump gene can be a halorhodopsin gene.
    Type: Application
    Filed: November 13, 2017
    Publication date: May 10, 2018
    Applicant: FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: David BALYA, Volker BUSSKAMP, Pamela LAGALI, Botond ROSKA
  • Patent number: 9862970
    Abstract: An isolated nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO:1, or a nucleic acid sequence of at least 1000 bp having at least 70% identity to the sequence of SEQ ID NO:1. The isolated nucleic acid molecule can lead to the expression of a gene in retinal ON bipolar cells when a nucleic acid sequence coding for a gene is operatively linked to the isolated nucleic acid molecule.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: January 9, 2018
    Assignee: FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Botond Roska, Pamela Lagali
  • Patent number: 9844579
    Abstract: The present inventions relates to the use of an isolated nucleic acid molecule comprising a nucleotide sequence coding for a hyperpolarizing light-gated ion channel or pump gene from an archeon or for a light-active fragment of said gene, or the nucleotide sequence complementary to said nucleotide sequence, for treating or ameliorating blindness. The light-gated ion channel or pump gene can be a halorhodopsin gene.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: December 19, 2017
    Assignee: Friedrich Miescher Institute for Biomedical Research
    Inventors: David Balya, Volker Busskamp, Pamela Lagali, Botond Roska
  • Publication number: 20170298360
    Abstract: The present invention relates to a method for treating breast cancer in a subject having a breast cancer of the estrogen receptor (ER?) negative type, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the Large Tumor Suppressor Kinase (LATS). Also provided are a siRNA decreasing or silencing the expression of the Large Tumor Suppressor Kinase (LATS), and an antibody specifically binding to the Large Tumor Suppressor Kinase (LATS), for use to treat breast cancer of the estrogen receptor (ER?) negative type.
    Type: Application
    Filed: September 23, 2015
    Publication date: October 19, 2017
    Applicant: FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Mohamed BENTIRES-ALJ, Adrian BRITSCHGI
  • Patent number: 9579399
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 200 bp having at least 70% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in cones and/or OFF bipolar cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: February 28, 2017
    Assignee: FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Botond Roska, Josephine Juettner
  • Publication number: 20160304865
    Abstract: The present inventions relates to isolated nucleic acid molecules comprising a nucleotide sequence coding for mi RNA-182 (uuuggcaaugguagaacucacacu or ugguucuagacuugccaacua), miRNA-96 (uuuggcacuagcacauuuuugcu or aaucaugugcagugccaauaug) and/or mi RNA-183 (uauggcacugguagaauucacu or gugaauuaccgaagggccauaa) for use in treating or ameliorating a ciliopathy and/or a photoreceptor dysfunction.
    Type: Application
    Filed: September 25, 2014
    Publication date: October 20, 2016
    Applicant: Friedrich Miescher Institute for Biomedical Research
    Inventors: Volker Busskamp, Witold Filipowicz, Jacek Krol, Botond Roska
  • Publication number: 20160138043
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1000 by having at least 70% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in ON bipolar cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Application
    Filed: June 10, 2014
    Publication date: May 19, 2016
    Applicant: Friedrich Miescher Institute for Biomedical Research
    Inventors: Botond ROSKA, Pamela LAGALI
  • Publication number: 20160130588
    Abstract: The present invention provides a method for generating polycystronic nucleic acid vectors, said method comprising the steps of a) providing a first nucleic acid vector, said first nucleic acid vector comprising: i) an origin of replication placed in front of ii) at least one first gene of interest functionally cloned within a first expression cassette, said first expression cassette comprising a promoter sequence as well as a termination sequence, said first gene of interest being located between said promoter sequence and said termination sequence, iii) a marker gene together with its termination sequence, said marker gene being situated downstream of a target sequence for a recombinase, wherein the promoter necessary for the expression of said marker gene in a host cell is absent from said first nucleic acid vector, and optionally iv) a first further marker gene which is different from the marker gene of iii), said first further marker gene being situated within said first expression cassette of ii) or with
    Type: Application
    Filed: March 14, 2014
    Publication date: May 12, 2016
    Applicant: FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (FMI)
    Inventors: Wassim Abdul RAHMAN, Nicolas Holger THOMÄ
  • Publication number: 20160123855
    Abstract: The present invention provides a method for preparing a sample for microscopy, said method comprising the steps of contacting said sample with a first polymerizable resin under conditions and for a time sufficient for penetration of said first polymerizable resin into the sample, removing excessive first polymerizable resin from the surface of the sample, contacting the so-prepared sample containing said first polymerizable resin with a second polymerizable resin preparation, said second polymerizable resin preparation comprising a high concentration of electrically conductive particles, and subjecting the so-prepared sample to the curing temperature of the polymerizable resins, wherein the curing temperature of said second polymerizable resin preparation is substantially the same as the curing temperature of the first polymerizable resin.
    Type: Application
    Filed: June 12, 2014
    Publication date: May 5, 2016
    Applicant: Friedrich Miescher Institute for Biomedical Research
    Inventors: Rainer FRIEDRICH, Christel GENOUD, Adrian WANNER
  • Publication number: 20150376597
    Abstract: The present invention provides a method for the targeted infection of cells. Said method is characterized in that it comprises the step of contacting the cell with a virus attached to a support. The present invention also encompasses a support to which a molecule binding specifically to a molecule present on the surface of a virus is attached, said molecule binding specifically to a molecule present on the surface of said virus being optionally attached to the support through a linking moiety.
    Type: Application
    Filed: February 6, 2014
    Publication date: December 31, 2015
    Applicants: FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH (FMI), Eldg. Technische Hochschule (ETH)
    Inventors: Kamill BALINT, Daniel Jobst MÜLLER, Botond ROSKA, Rajib SCHUBERT
  • Publication number: 20150344907
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 200 bp having at least 70% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in cones and/or OFF bipolar cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Application
    Filed: August 26, 2013
    Publication date: December 3, 2015
    Applicant: FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Botond ROSKA, Josephine JUETTNER